Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors

• Published in: Journal for immunotherapy of cancer Vol. 9; no. 7; p. e003048
• Main Authors: Fogli, Laura K, Aurigemma, Rosemarie, Sommers, Connie L, Singh, Anju, Bourcier, Kasia, Ernstoff, Marc S
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.07.2021; BMJ Publishing Group
• Subjects: Antigens; Cancer; Cancer therapies; Cell culture; Cell- and Tissue-Based Therapy - methods; Education - standards; Genetic engineering; Good Manufacturing Practice; History, 21st Century; Humans; Immune Cell Therapies and Immune Cell Engineering; Immunotherapy; Immunotherapy - methods; Lymphocytes; Manufacturing; Medical research; Metabolism; National Cancer Institute (U.S.); Neoplasms - drug therapy; Patients; R&D; Research & development; Tumors; United States; Workshops; United States; T-lymphocytes; chimeric antigen; adoptive; lymphocytes; receptors; cell therapy; immunotherapy; tumor-infiltrating
• DOI: 10.1136/jitc-2021-003048
• ISSN: 2051-1426

Cell-based immunotherapies have had remarkable success in the clinic, specifically in the treatment of hematologic malignancies. However, these strategies have had limited efficacy in patients with solid tumors. To better understand the challenges involved, the National Cancer Institute (NCI) convened an initial workshop with immuno-oncology thought leaders in December 2018 and a follow-up workshop in December 2020. The goals of the NCI workshops on cell-based immunotherapy for solid tumors were to discuss the current state of the field of cell-based immunotherapy, obtain insights into critical knowledge gaps, and identify ways in which NCI could facilitate progress. At both meetings, subjects emphasized four main types of challenges in further developing cell-based immunotherapy for patients with solid tumors: scientific, technical, clinical, and regulatory. The scientific barriers include selecting appropriate targets, ensuring adequate trafficking of cell therapy products to tumor sites, overcoming the immunosuppressive tumor microenvironment, and identifying appropriate models for these investigations. While mouse models may provide some useful data, the majority of those that are commonly used are immunodeficient and unable to fully recapitulate the immune response in patients. There is therefore a need for enhanced support of small early-phase human clinical studies, preferably with adaptive trial designs, to provide proof of concept for novel cell therapy approaches. Furthermore, the requirements for manufacturing, shipping, and distributing cell-based therapies present technical challenges and regulatory questions, which many research institutions are not equipped to address. Overall, workshop subjects identified key areas where NCI support might help the research community in driving forward innovation and clinical utility: 1) provide focused research support on topics such as tumor target selection, immune cell fitness and persistence, cell trafficking, and the immunosuppressive tumor microenvironment; 2) support the rapid translation of preclinical findings into proof of concept clinical testing, harmonize clinical trial regimens, and facilitate early trial data sharing (including negative results); 3) expand manufacturing support for cell therapies, including vectors and reagents, and provide training programs for technical staff; and 4) develop and share standard operating procedures for cell handling and analytical assays, and work with the Food and Drug Administration to harmonize product characterization specifications.